Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? / Pouillon, L; Van Stappen, J; Bossuyt, P; Danese, S; Peyrin-Biroulet, L. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY. - ISSN 1521-6918. - 32-33:(2018), pp. 17-25. [10.1016/j.bpg.2018.05.006]